reason magazine, law
in reference to: http://feeds.feedburner.com/reason/Articles (view on Google Sidewiki)
A small company can now advance its psychedelic into Phase 3. Here’s why
that matters to other psychedelic biotechs.
-
GH Research’s stock rallied after saying the FDA lifted a hold on its
experimental depression treatment.
50 minutes ago
Posts
No comments:
Post a Comment